In this study, we first demonstrated that the TGFβ3-Smad signalling pathway regulated DcR3 expression by activating the transcriptional activity of transcription factor Sp1 which, combined with the DcR3 promoter, indicates that DcR3 may be a promising therapeutic target for HCC. Here, SP1 is linked to hepatocellular carcinoma.